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Abstract
Neuron-microglia co-cultures treated with pro-inflammatory agents are a useful tool to study neuroinflammation in vitro,
where to test the potential neuroprotective effect of anti-inflammatory compounds. However, a great diversity of
experimental conditions can be found in the literature, making difficult to select the working conditions when considering
this approach for the first time. We compared the use of neuron-primary microglia and neuron-BV2 cells (a microglial cell
line) co-cultures, using different neuron:microglia ratios, treatments and time post-treatment to induce glial activation and
derived neurotoxicity. We show that each model requires different experimental conditions, but that both neuron-BV2 and
neuron-primary microglia LPS/IFN-c-treated co-cultures are good to study the potential neuroprotective effect of anti-
inflammatory agents. The contribution of different pro-inflammatory parameters in the neurotoxicity induced by reactive
microglial cells was determined. IL-10 pre-treatment completely inhibited LPS/IFN-c-induced TNF-a and IL-6 release, and
COX-2 expression both in BV2 and primary microglial cultures, but not NO production and iNOS expression. However, LPS/
IFN-c induced neurotoxicity was not inhibited in IL-10 pre-treated co-cultures. The inhibition of NO production using the
specific iNOS inhibitor 1400 W totally abolished the neurotoxic effect of LPS/IFN-c, suggesting a major role for NO in the
neurotoxic effect of activated microglia. Consequently, among the anti-inflammatory agents, special attention should be
paid to compounds that inhibit NO production.
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Introduction
The presence of reactive glia or neuroinflammation has been
described in all neurodegenerative diseases, and glial activation,
especially microglial activation, may contribute to the neuropa-
thology observed [1,2]. The inhibition of neuroinflammation has
been postulated as a putative target in the treatment of
neurodegenerative diseases, and research has focused on the study
of potential neuroprotective effects of anti-inflammatory agents in
experimental models of neurodegeneration occurring in the
presence of reactive glia.
In spite of the obvious differences between microglia in vivo and
in vitro, cultured microglia constitute a powerful tool to study how
different agents can modify microglial activation in response to
known CNS active agents [3]. In vitro approaches are often used to
characterize molecules and pathways involved in microglial
activation. Numerous studies have considered different types of
glial cultures treated with lipopolysaccharide (LPS) or pro-
inflammatory cytokines to characterize glial activation and to test
the potential anti-inflammatory effect of candidate compounds.
Experimental in vitro models of neurotoxicity induced by reactive
glia are useful in turn to test the potential neuroprotective effect of
anti-inflammatory agents, which can then be assayed in vivo [4–8].
The microglial content in rodent primary mixed neuron-glia
cultures is usually low, due to the fact that brain embryos
(embryonic day 15–16) are generally used to obtain neurons in
culture while glial cultures are optimally obtained from 2–3 days
postnatal brains. Although microglial cells populate the rodent
brain around embryonic day 10, a marked increase in the number
of microglia is observed in the CNS in the first few days after birth
[9]. As microglial cells are believed to play a critical role in the
neurotoxicity induced by reactive glia [1,2], the low amount of
microglia present makes difficult to study glial activation and the
resulting neurotoxicity in primary mixed neuron-glia cultures. An
exception is primary mesencephalic cultures, which show a higher
amount of microglial cells than cultures obtained from other brain
regions due to the fact that the substantia nigra is the brain area
with the highest microglia content [10,11]. However, mesence-
phalic cultures are mostly used when the interest is focused on
dopaminergic neurons. An experimental strategy to overcome the
low amount of microglial cells usually detected in primary mixed
neuron-glia cultures is the use of co-culture approaches, where
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variable amounts of microglial cells are added on top of mixed
neuron-glia cultures. Experimental conditions using co-cultures
show great variability between laboratories [12–16]. The neu-
ron:microglia ratio, the decision to use either primary cultures or
different cell lines, the animal source of the glial cultures (usually
mouse or rat) and the stimulus inducing glial activation all
determine differences in the degree of neurotoxicity induced by
reactive glial cells in neuron-glia co-cultures.
In the present study, we establish two experimental models of
neuroinflammation in vitro, comparing the use of primary
microglial cells and the microglial cell line BV2. Neuronal death
is produced in mouse neuron-microglia co-cultures after the
induction of glial activation using LPS/interferon (IFN)-c, but
different experimental conditions are needed when BV2 or
primary microglia are considered. We studied the contribution
of different pro-inflammatory parameters in the neurotoxicity
induced by reactive microglia in the co-cultures. To this end we
pre-treated neuron-microglia co-cultures with the classical anti-
inflammatory cytokine interleukin (IL)-10 and the inducible nitric
oxide synthase (iNOS) inhibitor 1400 W. We point out nitric oxide
(NO) as one of the main targets to be considered in anti-
inflammatory strategies leading to neuroprotection.
Methods
Ethics Statement
Experiments were carried out in accordance with the Guidelines
of the European Union Council (86/609/EU) and following the
Spanish regulations (BOE 67/8509-12, 1988) for the use of
laboratory animals, and the protocols were approved by the Ethics
Committee from the Barcelona University and the Ethics and
Scientific Committees from the CSIC (Permit Numbers: 217/11
and 218/11).
Cell Cultures
BV2 cells. The mouse microglial cell line BV2 (generated
from primary mouse microglia transfected with a v-raf/v-myc
oncogene, [17]) was cultured in RPMI-1640 medium (Invitrogen,
Carlsbad, CA), supplemented with 0.1% penicillin-streptomycin
(Invitrogen) and 10% heat-inactivated foetal bovine serum (FBS,
Invitrogen). Cells were maintained at 37uC in a 5% CO2
humidified atmosphere. For nitrite assay and tumor necrosis
factor (TNF)-a production, cells were seeded at a density of 56104
cells/mL (1.66104 cells/cm2), and for protein extraction at 105
cells/mL (2.46106 cells/cm2).
Primary cultures. Primary microglia-enriched cultures were
obtained from primary mixed glial cultures from 2- to 4-day-old
C57BL/6 mice. To obtain mixed glial cultures, cerebral cortices
were dissected, carefully stripped of their meninges, and digested
with 0.25% trypsin-EDTA solution (Invitrogen) for 25 min at
37uC. Trypsinization was stopped by adding an equal volume of
culture medium, to which 0.02% deoxyribonuclease I (Sigma-
Aldrich, St. Louis, MO) was added. The culture medium consisted
of Dulbecco’s modified Eagle medium-F-12 nutrient mixture
(Invitrogen) supplemented with 10% FBS, 0.1% penicillin-
streptomycin (Invitrogen), and 0.5 mg/mL amphotericin B
(FungizoneH, Invitrogen). Cells were pelleted (5 min, 200 g),
resuspended in culture medium, and brought to a single cell
suspension by repeated pipetting followed by passage through
a 100 mm-pore mesh. Cells were seeded at a density of 3.56105
cells/mL (1.26105 cells/cm2) and cultured at 37uC in a 5% CO2
humidified atmosphere. Medium was replaced every 5–7 days.
Microglial cultures were prepared by the mild trypsinization
method previously described in our group [18]. Briefly, after 19–
Figure 1. Glial activation and resulting neurotoxicity in neuron-
BV2 co-cultures. Neuronal viability (MAP2-ABTS-ELISA assay) in
neuron-BV2 co-cultures 24 h or 48 h after treatment with 100 ng/mL
LPS +0.5 ng/mL IFN-c (A) or 100 ng/mL LPS +5 ng/mL IFN-c (B). Results
are presented as % of MAP2 immunostaining vs each control. Bars are
means + SEM of three to five independent experiments. *p,0.05 and
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21 days in vitro (DIV) mixed glial cultures were treated for 30 min
with 0.06% trypsin in the presence of 0.25 mM EDTA and
0.5 mM Ca2+. This resulted in the detachment of an intact layer
of cells containing virtually all the astrocytes, leaving a population
of firmly attached cells identified as .98% microglia. The
microglial cultures were treated 24 h after isolation by this
procedure.
Primary cortical neuronal cultures were prepared from C57BL/
6 mice on embryonic day 16 according to the method described by
Frandsen and Schousboe [19]. Cells were seeded at a density of
86106 cells/mL (2.66105 cells/cm2) in poly-D-lysine hydrobro-
mide (Sigma-Aldrich) coated 48-well culture plates and cultured at
37uC in a 5% CO2 humidified atmosphere in Dulbecco’s modified
Eagle medium, (Biochrom AG, Berlin, Germany) with 10% FBS,
26.2 mM NaHCO3 and 31 mM glucose, 1 mg/mL insulin (Sig-
ma-Aldrich,), 30 mg/mL penicillin G (Sigma-Aldrich), 1 mg/mL
aminobenzoic acid and 0.2 mM L-glutamine (Sigma-Aldrich). In
some experiments KCl was added to the culture media to reach
a potassium concentration of 25 mM.
These cultures contained 76% neurons (positive for microtu-
bule-associated protein 2, MAP2, immunostaining), 17% astro-
cytes (positive for glial fibrillary acidic protein immunostaining),
,1% microglial cells (positive for CD11b immunostaining), and
6% other cell types. These neuron-glia cultures are called
‘‘neuronal cultures’’ here. Neuronal cultures were used at 5 DIV.
Co-cultures. For neuron-BV2 co-cultures BV2 cells growing
in T75–T150 culture flasks were gently scraped in neuronal
culture medium, and aliquots of the cell suspension (50 ml/well)
were seeded on top of 5 DIV primary neuronal cells at different
final densities (1.56105 cells/mL or 56104 cells/cm2, and 26105
cells/mL or 6.76104 cells/cm2, referred in the text as 1:5 and 1:4
BV2:neuron ratios respectively).
For neuron-primary microglia co-cultures microglial cultures
were obtained as described above. After the isolation, microglia-
enriched cultures were incubated with 0.25% trypsin for 10 min at
37uC. Trypsinization was stopped by adding the same volume of
culture medium with 10% FBS. Cells were gently scraped and
centrifuged for 5 min at 200 g. Pellet was resuspended in neuronal
culture medium and aliquots of the cell suspension (50 ml/well)
were seeded on top of 5 DIV primary neuronal culture at different
final densities (46105 cells/mL or 136104 cells/cm2, 26105 cells/
mL or 6.76104 cells/cm2, and 1.56105 cells/mL or 56104 cells/
cm2, referred in the text as 1:5, 1:4 and 1:2 microglia:neuron ratios
respectively).
Treatments
BV2 cells. One day after seeding, the culture medium was
replaced by fresh RPMI medium. One day later, cells were treated
with 100 ng/mL LPS (Sigma-Aldrich, E. coli serotype 026:B6) and
0.5 ng/mL recombinant mouse IFN-c (Sigma-Aldrich).
Mouse primary microglia. One day after isolation, micro-
glia-enriched cultures were treated with 100 ng/mL LPS and
30 ng/mL IFN-c.
A stock solution of 50 mg/mL IL-10 (Peprotech, Rocky Hill, NJ)
was prepared in DMEM:F-12 culture media and stored at220uC.
It was added to the culture media 1 h prior to LPS/IFN-c
treatment, at a final concentration of 50 ng/mL.
Neuron-BV2 co-cultures. 100 ng/mL LPS and 0.5 or 5 ng/
mL IFN-c were added to the culture medium 2 h after seeding
BV2 cells on top of neuronal cultures.
Neuron-primary microglia co-cultures. 100 ng/mL LPS
and 15 or 30 ng/mL IFN-c were added to the culture medium
one day after seeding primary microglial cells on top of neuronal
cultures.
1400 W dihydrochloride (Tocris, Ellisville, MO) was prepared
as a 900 mM stock solution in milliQ water and stored at 220uC.
It was added to the culture media at the same time as LPS/IFN-c
treatment, at a final concentration of 10 mM.
Nitrite Assay
NO production was assessed by the Griess reaction. Briefly,
culture supernatants were collected 24 h after LPS/IFN-c
treatment, and incubated with equal volumes of Griess reagent
for 10 min at room temperature. Optical density at 540 nm was
measured using a microplate reader (Multiskan spectrum, Thermo
electron corporation, Waltham, CA). Nitrite concentration was
calculated from a sodium nitrite standard curve.
Tumor Necrosis Factor (TNF)-a Assay
The amount of TNF-a released into the culture medium was
measured using an ELISA kit specific for mouse TNF-a (Mouse
TNFa ELISA Ready-SET-Go kit, eBioscience, San Diego, CA),
following manufacturer’s instructions. Culture supernatants were
collected 24 h after LPS/IFN-c treatment and stored at 280uC
until assayed for TNF-a content.
IL-6 Assay
The amount of IL-6 released into the culture medium was
measured using an ELISA kit specific for mouse IL-6 (Murine IL-6
Eli-pair, Diaclone, Besanc¸on, France), following the manufac-
turer’s instructions. Culture supernatants were collected 24 h after
LPS/IFN-c treatment and stored at 280uC until assayed for IL-6
content.
Isolation of Total Proteins
Total protein extracts were obtained as previously described
[20]. Inducible nitric oxide synthase and cyclooxygenase-2
expression were measured in total protein extracts from BV2
and primary microglial cells 12 h or 24 h after treatments, using 2
or 3 wells from 6-well plates for BV2 cells or mouse primary
microglia respectively for each experimental condition. Protein
amount was measured by Lowry assay (Total Protein kit micro-
Lowry, Sigma-Aldrich).
Western Blot Analysis
Around 20–40 mg of protein, of denatured (100uC for 5 min)
protein total extracts, was subjected to SDS-PAGE on a 7%
polyacrylamide gel, together with a molecular weight marker
(Fullrange Rainbow Molecular Weight Marker, Amersham,
Buckinghamshire, UK), and transferred to a PVDF membrane
(Millipore, Bedford, MA). After washing in Tris-buffered saline
(TBS: 20 mM Tris, 0.15 M NaCl, pH 7.5) for 5 min, dipping in
methanol for 10 s and air drying, the membranes were incubated
with primary antibodies overnight at 4uC: polyclonal rabbit anti-
COX-2 (1:2000, Santa Cruz Biotechnology), polyclonal rabbit
anti-NOSII (1:200, Chemicon, Temecula, CA) and monoclonal
mouse anti-ß actin (1:40000, Sigma-Aldrich) diluted in immuno-
blot buffer (TBS containing 0.05% Tween-20 and 5% non-fat dry
milk). Then, the membranes were washed twice in 0.05% Tween-
20 in TBS for 15 s and incubated in horseradish peroxidase
***p,0.001 vs each control, unpaired Student’s t-test. (C-H) MAP-2
immunostaining in control neuron-BV2 co-cultures (C, D) and co-
cultures treated with LPS 100 ng/mL + IFN-c 0.5 ng/mL for 24 h (E) or
48 h (G) and with LPS 100 ng/mL + IFN-c 5 ng/mL for 24 h (F) or 48 h
(H). Bar = 100 mm.
doi:10.1371/journal.pone.0045227.g001
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(HRP)-labelled secondary antibodies for 1 h at room temperature:
donkey anti-rabbit (1:5000, Amersham, Buckinghamshire, UK)
and goat anti-mouse (1:5000, Santa Cruz Biotechnology). After
extensive washes in 0.05% Tween-20 in TBS, they were incubated
in ECL-Plus (Amersham) for 5 min. Membranes were then
exposed to the camera of a VersaDoc System (Bio-Rad
Laboratories, Hercules, CA), and pixel intensities of the immuno-
reactive bands were quantified using the % adjusted volume
feature of Quantity One 5.4.1 software (Bio-Rad Laboratories).
Data are expressed as the ratio between the intensity of the protein
of interest band and the loading control protein band (b-actin).
Immunocytochemistry
Cultured cells were fixed with 4% paraformaldehyde in PBS for
20 min at room temperature. Cells were permeated and endog-
enous peroxidase activity was blocked by incubation with 0.3%
H2O2 in methanol for 10 min. Non-specific staining was blocked
by incubating the cells with 10% normal goat serum in PBS
containing 1% BSA for 20 min at room temperature. The cells
were then incubated with monoclonal mouse anti-MAP2 primary
antibody (1:4000, Sigma-Aldrich) overnight at 4uC, and with
biotinylated horse anti-mouse secondary antibody (1:200, Vector,
Burlingame, CA, USA) for 1 h at room temperature. Following
incubation with ExtrAvidin-HRP (1:500, Sigma-Aldrich) for 1 h at
room temperature, colour was developed with diaminobenzidine
(Sigma-Aldrich). The antibodies were diluted in PBS containing
1% BSA and 10% normal horse serum (Vector).
Microscopy images were obtained with an Olympus IX70
microscope (Olympus, Okoya, Japan) and a digital camera (CC-
12, Cell‘P Olympus Soft Imaging System GmbH, Hamburg,
Germany).
Assessment of Neuronal Viability
Neuronal viability was evaluated by MAP2 immunostaining
using ABTS (2,39-azino-bisethylbenzothiazoline-6-sulphonic acid)
as previously described [21]. Briefly, MAP2 staining was
performed using peroxidase labelling as described above, but
colour was developed using the ABTS Peroxidase Substrate Kit
(Vector) following the manufacturer’s instructions. Three wells per
experimental condition were processed, and each experimental
condition was repeated at least three times. One of the wells was
processed without primary antibody and used as background
control: its average absorbance was subtracted from sample
absorbance to calculate neuronal viability. Neuronal viability was
expressed as a percentage of control levels.
Data Presentation and Statistical Analysis
Results are presented as the means + SEM. Student’s two-tailed
t-test was used when two groups were considered. One-way
ANOVA followed by Newman-Keuls post-test or two-way
ANOVA followed by Bonferroni post-test were performed when
three or more experimental groups were compared. Values of
p,0.05 were considered statistically significant.
Results
Activation of Microglia with LPS/IFN-c had a Neurotoxic
Effect: Neuron-BV2 Co-cultures as an Experimental Model
of Neuroinflammation
As an experimental model of neuroinflammation in vitro, we
cultured BV2 cells on top of primary cortical neurons (at a ratio of
1:5) and we treated the co-cultures with 100 ng/mL LPS and
increasing concentrations of IFN-c (0.5 and 5 ng/mL). The
induction of neurotoxicity in response to glial activation was
evaluated 24 or 48 h after treatment. LPS alone or IFN-c alone
had no effect on neuronal viability in the co-cultures (Fig. S1).
However, although LPS +0.5 ng/mL IFN-c treatment did not
affect neuronal viability at 24 h, significant neurotoxicity was
observed at 48 h (Fig. 1A), measured as % of MAP2 immunos-
taining versus control as explained in Material and Methods. An
increased concentration of IFN-c (5 ng/mL) markedly enhanced
neurotoxicity in the co-cultures at 48 h (83617% neuronal death
using 5 ng/mL versus 44611% neuronal death using 0.5 ng/mL),
in the absence of any effect on neuronal viability at 24 h (Fig. 1B).
Figure 1C–H shows MAP2 immunocytochemistry in neuron-BV2
co-cultures treated with LPS +0.5 ng/mL IFN-c (left column) or
LPS +5 ng/mL IFN-c (right column). A clear decrease in
immunolabelling in the neuronal network was observed 48 h
after both treatments (Fig. 1G–H), but not at 24 h (Fig. 1E–F).
LPS + IFN-c treatments did not induce neurotoxicity in neuronal
cultures (data not shown).
The Neurotoxic Potential of Reactive BV2 Cells Increased
in the Presence of High Extracellular K+ Concentration
Acute brain injury is associated with increased extracellular K+
concentration, which has been reported to enhance neurotoxicity
induced by activated glial cells in vitro [22], suggesting that
extracellular K+ modulates neuroinflammation and the resulting
neurotoxicity. We determined whether an increase in K+
concentration in the culture media could potentiate the induction
of neuronal death in our experimental model of neuroinflamma-
tion in vitro. BV2 cells were added to neuronal cultures grown in
the presence of 5 mM KCl (low K+) or 25 mM KCl (high K+).
The effect of 100 ng/mL LPS +0.5 ng/mL IFN-c on neuronal
viability was determined 24 h after treatment, when neuronal
death was not observed in co-cultures grown in low K+ (Fig. 1). No
differences in neuronal viability were observed between control co-
cultures grown in high K+ and low K+ (Fig. 2A). However,
significant neuronal death was observed 24 h after LPS/IFN-c
treatment only in co-cultures grown in high K+ (Fig. 2A–C).
We also determined whether an increase in BV2:neuron ratio in
the co-cultures could further enhance the neurotoxicity of 100 ng/
mL LPS +0.5 ng/mL IFN-c treatment. However, increasing the
BV2:neuron ratio from 1:5 to 1:4 induced significant neurotoxicity
in the control co-cultures (Fig. 2D), without an increase in
neurotoxicity in the LPS/IFN-c treated co-cultures (Fig. 2E).
Figure 2. Increased extracellular K+ concentration enhanced reactive glia-induced. neurotoxicity in neuron-BV2 co-cultures. (A) Neuronal
viability (MAP2-ABTS-ELISA assay) in neuron-BV2 co-cultures grown in 5 mM and 25 mM KCl 24 h after 100 ng/mL LPS +0.5 ng/mL IFN-c treatment.
Results are presented as % of MAP2 immunostaining in control co-cultures grown in 5 mM KCl. Bars are means + SEM of four independent
experiments. ***p,0.001 vs respective control; two-way ANOVA (repeated measures) and Bonferroni post-test. (B) MAP2 immunostaining in control
(B) and 100 ng/mL LPS +0.5 ng/mL IFN-c treated co-cultures grown in high K+. Bar = 100 mm. (D) Increasing BV2:neuron ratio results in neurotoxicity
in control neuron-BV2 co-cultures. (E) Increasing BV2:neuron ratio does not result in increased neurotoxicity in 100 ng/mL LPS +0.5 ng/mL IFN-c
treated co-cultures.
doi:10.1371/journal.pone.0045227.g002
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Comparing Neuron-BV2 Co-cultures with Neuron-
primary Microglia Co-cultures to Establish an
Experimental Model of Neuroinflammation
The use of cell lines has many advantages, especially in the case
of microglial cells, as regards the amount of cells that can be easily
and rapidly obtained. However, in some cases cell lines respond to
certain stimuli in a different way than primary cultures.
Consequently, we studied possible differences between neuron-
BV2 and neuron-primary microglia co-cultures in our model of
neuroinflammation. Primary microglial cells were seeded on the
top of neuronal cultures at different microglia:neuron ratios, and
neuronal death was assessed after inducing glial activation with
100 ng/mL LPS and increasing concentrations of IFN-c (0.5 and
5 ng/mL). Unlike neuron-BV2 co-cultures, no significant neuro-
toxicity was observed in neuron-microglia co-cultures 48 h after
treatment using primary microglia:neuron ratios of 1:5, 1:4, nor at
a primary microglia:neuron ratio of 1:2 (data not shown). When
IFN-c concentration was increased to 15 and 30 ng/mL,
significant neurotoxicity was observed in neuron-primary micro-
glia co-cultures at a primary microglia:neuron ratio of 1:2 (Fig. 3A).
No neurotoxic effect of the treatments was observed in neuronal
cultures (Fig. 3A). No effect in neuronal viability was observed
following the addition of microglial cells in control co-cultures
(Fig. 3B). MAP2 immunocytochemistry shows no alterations in
neuronal cultures (Fig. 3C–D) and a clear decrease of staining in
the neuronal network in neuron-primary microglial co-cultures
48 h after 100 ng/mL LPS +30 ng/mL IFN-c-treatment (Fig. 3E–
F).
We also examined whether an increase in KCl concentration in
the culture media could potentiate the induction of neuronal death
in our experimental model of neuroinflammation in vitro using
primary microglial cells. Primary microglial cells were added to
neuronal cultures grown in the presence of 5 mM KCl (low K+) or
25 mM KCl (high K+), and the effect of 100 ng/mL LPS +30 ng/
mL IFN-c on neuronal viability was determined 48 h after
treatment. Unlike neuron-BV2 co-cultures, no significant differ-
ences were observed between neuron-primary microglia co-
cultures grown in low K+ and high K+ (Fig. 4).
Production of Pro-inflammatory Mediators by LPS/IFN-c-
treated Microglial Cells
In order to identify factors potentially responsible for the
neurotoxic effect of activated microglia in the co-cultures in our
two models of neuroinflammation, we first characterized the
production of pro-inflammatory molecules in BV2 and primary
microglial cultures in response to LPS/IFN-c. We detected an
increase in the release of the pro-inflammatory cytokines TNF-
a(Fig. 5A) and IL-6 (Fig. 5B) 24 h after treatment both in BV2 and
primary microglial cultures. We also observed an increase in the
expression of the pro-inflammatory enzymes COX-2 (Fig. 5C and
F) and iNOS (Fig. 5D and F) 12 h after treatment in both types of
cultures, as well as an increase in NO production (Fig. 5E).
Pre-treatment with the Anti-inflammatory Cytokine IL-10
did not Reverse LPS/IFN-c-Induced Neurotoxicity in
Neuron-microglia Co-cultures
Once the experimental model of neuroinflammation was
established, we tested whether the inhibition of the pro-in-
flammatory response resulted in neuroprotection, using the anti-
inflammatory cytokine IL-10. Nevertheless, IL-10 pre-treatment
(50 ng/ml) did not modify the neurotoxic effect of LPS/IFN-c
activated microglia, neither using primary microglia (Fig. 6) nor
BV2 cells (data not shown). We then evaluated whether IL-10 pre-
treatment was inhibiting the pro-inflammatory response induced
by LPS/IFN-c in microglial cells. Figure 7 shows the results
obtained using primary microglia cultures, but similar results were
obtained using BV2 cells (data not shown). TNF-a and IL-6
release induced by LPS/IFN-c were completely inhibited in IL-10
pre-treated cultures (Fig. 7A and B). In addition, drastic inhibition
of COX-2 expression was observed in the presence of IL-10 pre-
treatment (Fig. 7C and F). However, IL-10 pre-treatment did not
modify iNOS expression (Fig. 7D and F) or NO production
(Fig. 7E) induced by LPS/IFN-c.
NO is the Main Mediator of LPS/IFN-c-induced
Neurotoxicity in Neuron-primary Microglia Co-cultures
Among the different pro-inflammatory parameters that we
evaluated in microglial cultures in response to LPS/IFN-c, NO
production and iNOS expression were the only factors not
inhibited after IL-10 pre-treatment. Consequently, we next
analysed whether the selective inhibition of NO production could
reverse LPS/IFN-c-induced neurotoxicity in our co-cultures, using
the specific iNOS inhibitor 1400 W. We confirmed that 1400 W
treatment (10 mM) inhibited NO production induced by LPS/
IFN-c in neuron-primary microglia co-cultures (Fig. 8A), and we
Figure 3. Glial activation and resulting neurotoxicity in neuron-primary microglia co-cultures. (A) Neuronal viability (MAP2-ABTS-ELISA
assay) in neuronal cultures and neuron-primary microglia co-cultures 48 h after treatment with 100 ng/mL LPS and increasing concentrations of IFN-c
(15 and 30 ng/mL). (B) The addition of microglial cells at a microglia:neuron ratio of 1:2 did not result in neurotoxicity after 48 h. Results are presented
as % of MAP2 immunostaining vs each control. Bars are means + SEM of 3–4 independent experiments. *p,0.05 vs control; one-way ANOVA and
Newman-Keuls post-test. MAP-2 immunocytochemistry in neuronal cultures (C-D) and neuron-primary microglia co-cultures (E-F) in control
conditions (C and E) and 48 h after 100 ng/mL LPS +30 ng/mL IFN-c (D and F).
doi:10.1371/journal.pone.0045227.g003
Figure 4. High extracellular K+ concentration did not potenti-
ate reactive glia-induced neurotoxicity in neuron-primary
microglia co-cultures. Neuronal viability (MAP2-ABTS-ELISA assay)
in neuron-primary microglia co-cultures grown in 5 mM and 25 mM KCl
and treated with 100 ng/mL LPS +30 ng/mL IFN-c for 24 h. Results are
presented as % of MAP2 immunostaining in control co-cultures grown
in 5 mM KCl. Bars are means + SEM of four independent experiments.
**p,0.01 vs each control; two-way ANOVA (repeated measures) and
Bonferroni post-test.
doi:10.1371/journal.pone.0045227.g004
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observed that this effect was associated with the inhibition of LPS/
IFN-c-induced neurotoxicity (Fig. 8B).
Discussion
In the present work, we have established two experimental
models of neuroinflammation in vitro, co-culturing primary cortical
neurons either with the microglial cell line BV2 or with primary
microglia, and treating the co-cultures with LPS/IFN-c. We have
characterized differences in the experimental conditions required
in each co-culture to induce neurotoxicity, and subsequently
checked the potential neuroprotective effect of the anti-inflamma-
tory cytokine IL-10. Using IL-10, we show that the anti-
inflammatory properties of a compound do not always result in
neuroprotection. We also show that NO production by reactive
glial cells plays a critical role in the neurotoxicity observed in the
LPS/IFN-c-treated co-cultures.
Neuron-glia co-cultures can be used to test anti-inflammatory
and neuroprotective properties of selected candidate compounds.
Cell lines, either neuronal or glial, or primary cultures can be used
for this purpose. The presence of microglial cells in the co-cultures
is critical for the neurotoxic effect of glial activation. In fact, we did
not detect neurotoxicity in LPS/IFN-c-treated neuronal cultures
when microglial cells were not added, in spite of the significant
amount of astrocytes present. However, an indirect contribution of
astrocytes in the neurotoxicity observed in the co-cultures cannot
be ruled out. As regards the amount of microglial cells present in
the co-cultures, we observed that differences in the microglia:-
neuron ratio have to be taken into account when co-culturing
primary neuronal cultures with the microglial cell line BV2 or with
primary microglia.We observed that control neuronal cultures
survived better with added primary microglial cells than with
added BV2 cells. Thus, neuronal death was detected when
increasing BV2:neuron ratio from 1:5 to 1:4 in untreated co-
cultures, while a primary microglia:neuron ratio of 1:2 did not
modify neuronal viability per se. The toxic effect of high amounts of
BV2 cells on neuronal viability may be due, at least in part, to the
high metabolic rate associated with the elevated proliferation rate
of the immortalized cell line.
The stimulus used is also critical for the neurotoxic effect of glial
activation in the co-cultures. While LPS or IFN-c alone did not
Figure 5. Pro-inflammatory response in BV2 and primary
microglia cell cultures in response to LPS/IFN-c. BV2 cells were
treated 100 ng/mL of LPS +0.5 ng/mL of IFN-c and primary microglial
cells with 100 ng/mL LPS +30 ng/mL IFN-c, and different pro-
inflammatory parameters were measured. TNF-a (A) and IL-6 (B) levels
were determined in the culture medium 24 h after treatment. COX-2 (C)
and iNOS protein expression (D) were measured by western blot 12 h
after treatment, and data normalized by b-actin. NO production (E) was
determined in the culture medium 24 h after treatment. Bars are means
+ SEM of four to six independent experiments. *p,0.05 and **p,0.01
vs control; paired Student’s t test. (F) shows representative western
blots.
doi:10.1371/journal.pone.0045227.g005
Figure 6. IL-10 pre-treatment did not inhibit the neurotoxicity
induced by reactive microglia in neuron-primary microglia co-
cultures. Neuron-primary microglia co-cultures were treated with
100 ng/mL LPS +30 ng/mL IFN-c for 48 h in the presence or absence of
50 ng/mL of IL-10 administered 1 h prior to LPS/IFN-c. Evaluation of
neuronal viability by MAP2-ABTS-ELISA assay. Results are presented as
% of MAP2 immunostaining in control co-cultures. Bars are means +
SEM of four independent experiments. **p,0.01 vs control; one-way
ANOVA (repeated measures) and Newman-Keuls post-test.
doi:10.1371/journal.pone.0045227.g006
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Figure 7. IL-10 pre-treatment inhibited the pro-inflammatory response induced by LPS/IFN-c in primary microglia cultures. Primary
microglial cultures were treated with 100 ng/mL LPS +30 ng/mL IFN-c for 24 h in the presence or absence of 50 ng/mL IL-10 administered 1 h prior
to LPS/IFN-c. TNF-a (A) and IL-6 (B) levels were determined in the culture medium 24 h after treatment. (C) COX-2 and (D) iNOS protein expression
were measured by western blot 24 h after treatment, and data normalized by b-actin. (E) NO production was determined in the culture medium 24 h
after treatment. Bars are means + SEM of three to four independent experiments. *p,0.05, **p,0.01 and ***p,0.001 vs control; ###p,0.001 vs
LPS/IFN-c; one-way ANOVA (repeated measures) and Newman-Keuls post-test. (F) shows a representative western blot.
doi:10.1371/journal.pone.0045227.g007
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produce neurotoxicity, a neurotoxic effect was observed when the
two stimuli were used together to induce glial activation, once
a critical concentration of IFN-c was considered. These results
suggest that a critical threshold of glial activation has to be reached
to result in a neurotoxic effect. However, different patterns of
treatment have to be considered to attain this degree of activation
in BV2 and primary microglia. The amount of IFN-c added to
100 ng/mL LPS necessary to activate the microglial cells in order
to induce significant neurotoxicity was higher in neuron-primary
microglia co-cultures (15 or 30 ng/mL), where a higher micro-
glia:neuron ratio (1:2) was also necessary, than in neuron-BV2 co-
cultures (0.5 ng/mL IFN-c). In addition, high extracellular K+
levels made neurons more sensitive to neurotoxicity induced by
reactive BV2 cells but not to that induced by reactive primary
microglia. Differences between reactive BV2 and primary
microglia are also manifested when looking at the production of
pro-inflammatory factors in response to LPS/IFN-c treatment.
Although the results obtained can not be quantitatively compared
due to the differences in cell density between BV2 and primary
microglia cultures, both types of culture produce comparable
amounts of TNF-a, but NO production is higher and IL-6 lower
in BV2 cultures than in primary microglia cell cultures. All these
pro-inflammatory molecules are potentially neurotoxic by them-
selves or in combination, but the final neurotoxicity observed in
the co-cultures may result both from the contribution of microglia
secreted products and the interaction between the different cell
types present, which in turn will depend on the microglia cell type
(BV2 or primary microglial cells).
Both neuron-BV2 and neuron-primary microglia co-cultures
can be useful to establish an in vitro model of neuroinflammation,
and both of them have particular advantages. On the one hand,
apart from constituting an alternative to reduce the use of
experimental animals [23], the use of the BV2 cell line makes large
amounts of microglial cells available when necessary, which
overcomes the special difficulty of obtaining significant amounts of
primary microglial cells. On the other hand, the use of primary
microglial cells is closer to the physiological situation. Nevertheless,
since immortalization significantly affects a cell’s biology, and
differences in BV2 and primary microglia responses to different
stimuli have been described [24–25], the use of primary cultures to
validate results obtained using BV2 is recommended.
In glial cultures, different pro- and anti-inflammatory cytokines,
as well as reactive oxygen and nitrogen species, are produced in
response to LPS treatment. These factors are involved in the
Figure 8. The iNOS inhibitor 1400 W prevented the neurotoxicity induced by reactive microglia in neuron-primary microglia co-
cultures. Neuron-primary microglia co-cultures were treated with 100 ng/mL LPS +30 ng/mL IFN-c for 48 h in the presence or absence of 1400 W
(10 mM) co-administered with LPS/IFN-c. (A) NO production 48 h after LPS/IFN-c treatment. (B) Evaluation of neuronal viability by MAP2-ABTS-ELISA
assay. Results are presented as % of MAP2 immunostaining in control co-cultures. Bars are means + SEM of three independent experiments. **p,0.01
vs control; ##p,0.01 vs LPS/IFN-c; one-way ANOVA (repeated measures) and Newman-Keuls post-test.
doi:10.1371/journal.pone.0045227.g008
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inflammatory response of reactive glial cells and the resolution of
the inflammation. IL-10 is a classic immunoregulatory and anti-
inflammatory cytokine. Several authors have shown the inhibitory
effect of IL-10 treatment on the production of pro-inflammatory
cytokines by reactive glia in response to LPS [26–28]. In
accordance with these results, we observed that IL-10 pre-
treatment clearly inhibited IL-6 and TNF-a production as well
as COX-2 expression induced by LPS/IFN-c treatment in
microglial cultures (primary microglia and BV2 cells). Contradic-
tory results have been described regarding IL-10 inhibition of NO
production in LPS-treated glial cells [26,27,29,30]. IL-10 pre-
treatment did not inhibit NO production or iNOS expression in
LPS/IFN-c-treated microglial cultures. These results show a dif-
ferential regulation of pro-inflammatory molecules by IL-10 in
reactive mouse microglia.
Different studies demonstrate the neuroprotective effect of IL-
10 in vivo or in vitro against LPS- [31,32], glutamate- [33], oxygen-
glucose-deprivation- [34] and transection- induced neuronal
damage [35]. However, a lack of neuroprotective effect of IL-10
against neuronal damage, conflicting results, or even a deleterious
effect of IL-10, have also been reported in different experimental
in vivo approaches [32,36–38]. The neuroprotective action of Il-10
is attributed, at least in part, to the inhibition of pro-inflammatory
microglial activation, although a direct effect of the cytokine on
neuronal viability has also been described. Although we observed
that IL-10 inhibited the production of TNF-a and IL-6 and the
induction of COX-2 in LPS/IFN-c-treated microglial cells, we did
not observe neuroprotection after IL-10 pre-treatment in LPS/
IFN-c-treated mouse neuron-microglia co-cultures. As IL-10 pre-
treatment did not inhibit NO production induced by LPS/IFN-c
and the iNOS inhibitor 1400 W had a strong neuroprotective
effect in our experimental model, the lack of effect of IL-10 on NO
production may be responsible for the absence of neuroprotection.
These results suggest that, although a synergistic action of the
different pro-inflammatory molecules produced by reactive glial
cells cannot be ruled out, NO production plays a major role in
reactive microglia induced neurotoxicity. NO can induce neuronal
cell damage by disrupting the neuronal mitochondrial electron
transport chain [39,40]. In addition, NO may react with
superoxide ion produced by glial NADPH oxidase to generate
peroxynitrite [41], which in turn induces neurotoxicity through
the inhibition of mitochondrial respiration, the induction of
neuronal apoptosis and the induction of glutamate release
resulting in excitotoxicity [41,42]. NO can also cause protein
nitration and S-nitrosylation, resulting in loss of function and
neurotoxicity [43]. Consequently, NO production by reactive glial
cells probably contributes to neurotoxicity either directly or
through peroxynitrite and is a potential target to be considered
in neuroprotective strategies aimed to reduce neuronal death
associated with neuroinflammation.
In conclusion, neuron-BV2 and neuron-primary microglia
LPS/IFN-c-treated co-cultures are a useful tool with which to
study the potential neuroprotective effect of anti-inflammatory
agents. However, different experimental conditions have to be
established when using primary microglia or BV2 cells. In
addition, results obtained using BV2 cells have to be confirmed
with primary microglia to discard possible modifications in the
behaviour of the microglial immortalized cells. We show that the
anti-inflammatory properties of a compound do not always result
in neuroprotection and that, among the anti-inflammatory agents,
special attention should be paid to those compounds that inhibit
NO production. Nevertheless, although in vitro studies are a useful
tool to test anti-inflammatory and neuroprotective properties of
compounds, the in vivo context in each situation of CNS injury will
finally define the anti-inflammatory and neuroprotective effects of
a compound.
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